

Programme

Sunday September 13, 2015

Optional excursions

Welcome reception with Belgian Beers

Monday September 14, 2015

Registration

Welcome address

Plenary Session

Session Chair

Prof. Koen AUGUSTYNS
(UNIVERSITY OF ANTWERP, Antwerp, Belgium)

Discovery and Development of Bedaquiline: A Rocky Road

Prof. Koen ANDRIES
(JANSSEN PHARMACEUTICA NV, Beerse, Belgium)

Regulated Necrosis: Disease Relevance and Therapeutic Opportunities

Prof. Peter VANDENABEELE
(UNIVERSITY OF GHENT, Ghent, Belgium)

Coffee break and Exhibition

The Role of CXCR4 Modulators in Controlling HIV Entry, Stem Cell Mobilisation and Certain Types of Cancer

Prof. Dennis LIOTTA
(EMORY UNIVERSITY, Atlanta, United States)

Lunch and Exhibition

Session 1 - Molecular Chaperones and their Therapeutic Potential

Session Chair

Prof. Brian S. J. BLAGG
(UNIVERSITY OF KANSAS, Notre Dame, United States)

Story of the Hsp27 Inhibitor Apatorsen

Dr Palma ROCCHI
(MARSEILLE CANCEROLOGY RESEARCH CENTER, Marseille, France)

Targeting Protein-Protein Interactions in the Heat Shock Protein 70 (Hsp70) Complex

Prof. Jason GESTWICKI
(UNIVERSITY OF CALIFORNIA, San Francisco, United States)

Update on Hsp90 Inhibitors as Cancer Therapeutics

Dr Weiwen YING
(SYNTA PHARMACEUTICALS, Lexington, United States)

Oral Communications

Programme

**The Discovery of Chemical Probes for Bromodomain Containing Proteins
Prize winner EFMC-YMCS 2014**

Dr Duncan HAY
(EVOTEC, Abingdon, United Kingdom)

The Discovery Of A New Validated Target For Tuberculosis Via Phenotypic Screening

Ms Raquel FERNANDEZ
(GLAXOSMITHKLINE, Tres Cantos, Spain)

Measuring The Dynamics Of Target Engagement Inside Cells Using Bret

Mr Matthew ROBERS
(PROMEGA, Madison, United States)

Outcome EFMC video competition

Coffee break and Exhibition

**Poster Session 1
(posters with odd numbers)**

City Tour

Tuesday September 15, 2015

Session 2 - Unexplored Chemical Space: Experiences from the European Lead Factory and the NIH

Session Chair

Dr Peter MOLENVELD
(MERCACHEM-SYNCOM, Nijmegen, The Netherlands)

Sanford-Burnham's Experience with the NIH's Molecular Libraries Program

Dr Anthony PINKERTON
(SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE, La Jolla, United States)

Sharing Compound Collections: UCB's First Experiences from the European Lead Factory

Dr Jeremy DAVIS
(UCB, Slough, United Kingdom)

Privileged Structures Unlocking Therapeutic Target Families

Dr Gerhard MUELLER
(MERCACHEM, Basel, Germany)

Coffee break and Exhibition

Session 3 - Emerging Advances in GPCR Research

Session Chair

Dr Laurent PROVINS
(UCB, Braine-l'Alleud, Belgium)

Revealing The Structural Basis for GPCR Drug Action through Atomic-Level Simulation

Prof. Ron DROR
(STANFORD UNIVERSITY, Stanford, United States)

Towards 3rd Generation Antihistamines: Fact or Fiction?

Prof. Rob LEURS
(VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)

The Design of mGlu2 Negative Allosteric Modulators for the Treatment of Neuropsychiatric Disorders

Dr Michiel VAN GOOL
(JANSSEN R&D, Toledo, Spain)

Lunch and Exhibition

Poster Session 2 (posters with even numbers)

Session 4 - Novel Strategies for Anti-Thrombotic Therapy

Session Chairs

Dr Amjad ALI (MERCK & CO. INC., Kenilworth, United States)
Dr Amy RIPKA (WUXI APPTEC, Cambridge, United States)

Programme

Targeting Factor XII in Thrombosis and Inflammation

Prof. Thomas RENNE
(KAROLINSKA INSTITUTET, Stockholm, Sweden)

Structure-Based Design of Inhibitors of Factor XIa

Dr James CORTE
(BRISTOL MYERS SQUIBB, Princeton, United States)

Vorapaxar Discovery and Clinical Benefits

Dr Patrick ANDRE
(MERCK & CO., Kenilworth, United States)

Coffee break and Exhibition

Session 5 - Academic Drug Discovery (+ Panel discussion)

Session Chair

Prof. Henk TIMMERMAN
(VU UNIVERSITY AMSTERDAM, Oegstgeest, The Netherlands)

Translating Medicinal Chemistry Research into Targeted Therapeutics. Building on Academic Knowledge

Prof. Roberto PELLICCIARI
(UNIVERSITY OF PERUGIA, Corciano, Italy)

Science, Business & Innovation in Medicinal Chemistry

Prof. Iwan DE ESCH
(VU AMSTERDAM, Amsterdam, The Netherlands)

Panel Discussion - Introduction by the moderator

Panellist 1

Prof. Christa MÜLLER
(UNIVERSITY OF BONN, Bonn, Germany)

Panellist 2

Prof. Chas BOUNTRA
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

Panellist 3

Prof. Dennis LIOTTA
(EMORY UNIVERSITY, Atlanta, United States)

Panel Discussion with Roberto Pellicciari, Iwan de Esch, Christa Müller, Chas Bountra and Dennis Liotta, and discussion with the audience

End of Panel Discussion

Banquet at Grand Café Horta

Wednesday September 16, 2015

Session 6 - Non-Small Molecules

Session Chair

Prof. Steven FIRESTINE
(WAYNE STATE UNIVERSITY, Detroit, United States)

High Affinity Bicyclic Peptides: Application to Payloads in Oncology

Dr Gavin BENNETT
(BICYCLE THERAPEUTICS, Cambridge, United Kingdom)

Exploring Macrocycles for Protein-protein Interaction Targets: the Discovery of Novel Bifunctional XIAP Antagonists

Dr Nick TERRETT
(ENSEMBLE THERAPEUTICS CORPORATION, Kriens, Switzerland)

Discovery and Optimisation of Bioactive Macrocycles from DNA-Encoded Libraries

Dr Patrick MCENANEY
(THE SCRIPPS RESEARCH INSTITUTE, La Jolla, United States)

Coffee break and Exhibition

Session 7 - Emerging Topics

Session Chair

Dr Pascal GEORGE
(SCT & INDEPENDENT SCIENTIFIC EXPERT & ADVISER, Longvilliers, France)

Discovery of Highly Efficacious Potentiators for the Treatment of Cystic Fibrosis

Dr. Steven VAN DER PLAS
(ITEOS THERAPEUTICS, Belgium)

Discovery & Optimisation of Novel Antagonists to the Human Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders: From Hit to Clinic

Dr Hamid HOVEYDA
(EUROSCREEN, Woluwe-Saint-Lambert, Belgium)

Selective JAK1 Inhibitor for the Treatment of Autoimmune Diseases

Dr Michael L. VAZQUEZ
(PFIZER, Cambridge, United States)

Discovering A Potent Allosteric Kinase Modulator Employing A Computational And Synthetic Toolbox

Mr Edwin KROON
(UNIVERSITY OF GRONINGEN, Groningen, The Netherlands)

Lunch and Exhibition

Session 8 - Kinetics and Thermodynamics of Ligand Binding

Session Chair

Programme

Dr Matthias FRECH
(MERCK, Darmstadt, Germany)

Kinetics in Drug discovery - A Case for the Adenosine Receptors

Mr Dong GUO
(LEIDEN UNIVERSITY, Leiden , The Netherlands)

Drug Target Residence Time: HSP90, a Model to Gain Insight into the Molecular Mechanism of Binding

Dr Matthias FRECH
(MERCK, Darmstadt, Germany)

Novel JAK Inhibitors for Inhaled and Topical Delivery

Dr Peter JONES
(PFIZER, Cambridge, United States)

Coffee break and Exhibition

Session 9 - Rational Design of Non-Oral Drugs

Session Chair

Dr Jordi GRACIA
(ALMIRALL, Toulouse, France)

Inhaled PDE4 Inhibitors with Low Emetic Potential and Long Duration of Action for the Treatment of COPD

Dr Chris DE SAVI
(ASTRAZENECA R&D, Boston, United States)

A Novel Retinoic Acid Receptor Agonist for Dermatological Indications with Specific Design Parameters for Topical Administration to Manage Safety

Dr Claire BOUIX-PETER
(GALDERMA R&D, Sophia-Antipolis, France)

Locally-acting ROCK Inhibitors for the Treatment of Eye Diseases

Dr Olivier DEFERT
(AMAKEM, Loos, France)

Closing remarks